Updated: Dec 12, 2007
Paget disease of the bone (osteitis deformans) is a metabolic disorder characterized by abnormal osseous remodeling. Sir James Paget first described Paget disease in 1877 as a chronic inflammatory remodeling disease of bones. He termed the condition osteitis deformans.1
(See also the eMedicine articles Bone Metastases and Paget Disease [in Rheumatology], as well as Novel approach to Paget's disease: Targeting osteoclastogenesis, on Medscape.)
The etiology of Paget disease is uncertain, but it may be caused by a viral infection, possibly of the Paramyxoviridae family.2 Genetic predisposition to the development of Paget disease may exist as well. Clustering within families has been reported, supporting this theory. In addition, regional differences in disease prevalence support a significant environmental influence.3,4,5
Paget disease evolves through 3 stages as follows:
Paget disease rarely is diagnosed in the initial lytic phase. At this early point of the disease, osteoclastic activity is predominant. Paget disease usually begins at the end of a bone, except when it occurs in the tibia. A characteristic sharply demarcated zone of osteolysis may begin in the subcortical bone and advance along the diaphysis. Osteoblastic activity lags behind; thus, radiolucent fibrous tissue replaces normal bone.
The intermediate or mixed phase reveals evidence of osteolytic and disorganized osteoblastic activity. New bone forms abnormally and demonstrates characteristically coarsened trabecula and cortical thickening in the cancellous and compact bone, respectively. Characteristic intracytoplasmic inclusions may be observed microscopically, supporting evidence for the viral etiology theory.
The final or cold phase demonstrates less evidence of continual osseous remodeling. Previously laid down woven bone is converted to dense lamellar bone. Histologic features of disorganized bone are prominent. The intersecting lines of remodeled bone have a characteristic mosaic pattern histologically (see Image 1).
Paget disease occurs more commonly in the northern regions than in the southern regions, supporting the role of environmental influence in Paget disease. Paget disease affects 3-4% of the general population older than 40 years in the US.6
Paget disease may be found in more than 10% of the population older than 85 years. Paget disease is common in England and throughout Europe, except Scandinavia, and in New Zealand, Australia, and North America. Paget disease is rare in Asia and most of Africa, excluding South Africa (with its European immigrant population).7,8,9
Patients usually are asymptomatic, although the most frequent symptom is pain. Complications include insufficiency and pathologic fractures, secondary arthritis, nerve impingement in the spine or skull base, and, rarely, sarcomatous degeneration of the pagetic bone.10
Development of secondary sarcoma in pagetic bone is the most lethal complication, occurring in 1% or fewer of patients with Paget disease (see Image 2). These sarcomas are aggressive and may be multicentric. The 5-year survival rate is almost zero. Histology most frequently demonstrates osteosarcoma, with malignant fibrous histiocytoma accounting for most of the remaining tumors.11,12,13
Chemotherapeutic regimens are relatively ineffective and often quite toxic, particularly since there is a high likelihood of concurrent disease in these patients, who are typically older persons. Surgical intervention often is palliative at best. However, if diagnosed in the appendicular skeleton before metastases are present, surgical treatment may improve the chance of survival. Pagetic sarcoma may present with pain or pathologic fracture. Alkaline phosphatase levels may increase but occasionally remain normal.14,10
Multiple giant cell tumors rarely are observed in association with Paget disease. The usual sites of involvement are the skull and facial bones. These lesions often respond well to steroid therapy.15
Paget disease is more common in black Americans than in black Africans and is rare in Asians.
The male-to-female ratio is approximately 1.8:1.
Paget disease typically is seen in older individuals and is uncommon before age 45 years. Onset of disease may occur earlier in men than in women.
Paget disease may be monostotic but more commonly is polyostotic. The bones most frequently affected are the pelvis, calvaria, lumbar and thoracic spine, femur, tibia, and humerus.
Most patients with Paget disease are asymptomatic, and the disease is discovered incidentally. However, patients may develop a variety of signs and symptoms, depending on the site and severity of involvement.16,14
The most frequent complaint is pain, most commonly in the back and hip, followed by pain in the long bones and pelvis. Weight bearing may exacerbate pain in the spine, pelvis, or lower extremity. Disease in the skull may be accompanied by headache. Deafness also may occur from cranial nerve compression or middle-ear ossicle involvement. Pain may be present from secondary arthritis or nerve compression. Secondary arthritis most often affects the hips, knees, and ankles. Lower extremity limb shortening may be secondary to bowing of the tibia and femur.
Insufficiency fractures may present with pain that can last up to several weeks. If pain is focal and severe, it may be a sign of an impending, complete fracture, and radiographic evaluation is warranted. Insufficiency fractures most frequently affect the femur and tibia.
Consider medical treatment when a biochemically active disease may lead to complications or when significant disease is found in high-risk sites such as the proximal femur (see Image 3). Involvement in such a critical weight-bearing location may lead to fracture (see Image 4) or severe secondary arthritis. In addition, consider treatment in the presence of severe symptoms, such as bone pain or nerve compression, and prior to orthopedic surgical intervention within pagetic bone. Typical treatment regimens include analgesic and antiresorptive medications such as bisphosphonates.17,10
The radiographic findings of Paget disease are diagnostic in many patients. The lytic stage most commonly is observed in the skull and long bones. The typical appearance in the long bones is osteolysis, which begins in the epiphysis and advances along the diaphysis. Trabecular coarsening and distortion and cortical thickening are observed in the sclerotic phase, typically involving the axial skeleton.
Radiographic findings in Paget disease often are pathognomonic, particularly in the lytic phase. However, given the variable imaging appearance of Paget disease in different stages, as well as the many different bones involved, the differential diagnosis may vary substantially among patients.
Bone Metastases
Fibrous Dysplasia
Bony sclerosis without osseous enlargement, including blastic metastases, myelofibrosis, renal osteodystrophy, fibrous dysplasia, fluorosis, mastocytosis, and tuberous sclerosis
Coarsened trabecula in the axial skeleton with osteomalacia
Calvarial hyperostosis with hyperostosis frontalis interna, fibrous dysplasia, anemia, and metastatic disease
Hyperphosphatasia (juvenile Paget disease) in young patients
Characteristic radiographic findings include the following:
Cross-sectional MRI and CT demonstrate enlarged bones with trabecular coarsening and increased cortical thickness (see Images 15-16). The anatomy is well demonstrated by cross-sectional imaging in complex structures, such as the spine, where spinal or nerve root compression may be an issue (see Image 17). Cross-sectional imaging also helps delineate the pathology in complicated Paget disease, which includes nerve or spinal cord compression, as well as basilar invagination at the skull base and osseous encroachment involving cranial nerve foramina. Secondary sarcomatous development also is better evaluated with cross-sectional imaging. Additionally, should biopsy be indicated for the diagnosis of sarcoma, CT typically is the guidance modality of choice.
See CT Scan section.
Skeletal scintigraphy is useful. Radionuclide bone scans are more sensitive than radiographs for the diagnosis of Paget disease. Additionally, bone scans help survey the different sites of involvement with polyostotic disease (see Image 18). Characteristically, a marked uptake of radiopharmaceutical in the involved bones is observed (see Image 19). However, late-stage involvement may not reveal intense radiopharmaceutical uptake, and osteoporosis circumscripta may demonstrate only a peripheral rim of increased uptake. Scintigraphy tends to follow the physiologic activity of disease and may monitor treatment. Polyostotic Paget disease often can be distinguished from multiple metastatic lesions, although occasional difficulties occur. Perform radiographic correlation when this situation arises. Furthermore, the diagnosis of fracture or sarcoma may be challenging, often requiring multimodality correlation.
Biopsy often is needed to diagnose Paget sarcoma. In such cases, CT typically is the modality of choice for guidance.
Paget J. On a form of chronic inflammation of bones (osteitis deformans). Med Chir Tr. 1877;60:37.
Singer FR. Update on the viral etiology of Paget''s disease of bone. J Bone Miner Res. Oct 1999;14 Suppl 2:29-33. [Medline].
Barker DJ. The epidemiology of Paget''s disease of bone. Br Med Bull. Oct 1984;40(4):396-400. [Medline].
Siris ES, Ottman R, Flaster E. Familial aggregation of Paget''s disease of bone. J Bone Miner Res. May 1991;6(5):495-500. [Medline].
Layfield R. The molecular pathogenesis of Paget disease of bone. Expert Rev Mol Med. 2007;9(27):1-13. [Medline].
Guyer PB, Chamberlain AT. Paget''s disease of bone in two American cities. Br Med J. Apr 5 1980;280(6219):985. [Medline].
Barker DJ, Clough PW, Guyer PB. Paget''s disease of bone in 14 British towns. Br Med J. May 7 1977;1(6070):1181-3. [Medline].
Schmorl G. Ueber Ostitis deformans Paget. Virchows Arch. 1932;283:694-751.
Rojas-Villarraga A, Patarroyo PA, Contreras AS, Restrepo JF, Iglesias-Gamarra A. Paget disease of bone in Colombia and Latin America. J Clin Rheumatol. Apr 2006;12(2):57-60. [Medline].
Harrington KD. Surgical management of neoplastic complications of Paget''s disease. J Bone Miner Res. Oct 1999;14 Suppl 2:45-8. [Medline].
Smith J, Botet JF, Yeh SD. Bone sarcomas in Paget disease: a study of 85 patients. Radiology. Sep 1984;152(3):583-90. [Medline].
Deyrup AT, Montag AG, Inwards CY, Xu Z, Swee RG, Krishnan Unni K. Sarcomas arising in Paget disease of bone: a clinicopathologic analysis of 70 cases. Arch Pathol Lab Med. Jun 2007;131(6):942-6. [Medline].
, Sharma H, Mehdi SA, MacDuff E, Reece AT, Jane MJ. Paget sarcoma of the spine: Scottish Bone Tumor Registry experience. Spine. May 20 2006;31(12):1344-50. [Medline].
Hamdy RC. Paget's Disease of the Bone: Assessment and Management. Westport, CT:. Greenwood Publishing Group;1981.
Gebhart M, Vandeweyer E, Nemec E. Paget''s disease of bone complicated by giant cell tumor. Clin Orthop. Jul 1998;(352):187-93. [Medline].
Altman RD, Collins B. Musculoskeletal manifestations of Paget''s disease of bone. Arthritis Rheum. Oct 1980;23(10):1121-7. [Medline].
Tiegs RD. Paget''s disease of bone: indications for treatment and goals of therapy. Clin Ther. Nov-Dec 1997;19(6):1309-29; discussion 1523-4. [Medline].
osteitis deformans, Paget's disease
Mitchell J Kline, MD, Consulting Staff, Department of Diagnostic Radiology, University of Louisville, Clark Memorial and Floyd Memorial Hospitals
Mitchell J Kline, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Radiology, American Roentgen Ray Society, Radiological Society of North America, and Society of Skeletal Radiology
Disclosure: Nothing to disclose.
Leon Lenchik, MD, Director, Densitometry Minifellowship, Assistant Professor, Department of Radiology, Wake Forest University Medical Center
Leon Lenchik, MD is a member of the following medical societies: American College of Radiology, American Roentgen Ray Society, and Radiological Society of North America
Disclosure: Nothing to disclose.
Bernard D Coombs, MB, ChB, PhD, Consulting Staff, Department of Specialist Rehabilitation Services, Hutt Valley District Health Board, New Zealand
Disclosure: Nothing to disclose.
Wilfred CG Peh, MD, MBBS, FRCP(Glasg), FRCP(Edin), FRCR, MHSM, Clinical Professor, Faculty of Medicine, National University of Singapore; Senior Consultant Radiologist, Programme Office, Singapore Health Services
Wilfred CG Peh, MD, MBBS, FRCP(Glasg), FRCP(Edin), FRCR, MHSM is a member of the following medical societies: American Roentgen Ray Society, British Institute of Radiology, International Skeletal Society, Radiological Society of North America, Royal College of Physicians, and Royal College of Radiologists
Disclosure: Nothing to disclose.
Robert M Krasny, MD, Consulting Staff, Department of Radiology, The Angeles Clinic and Research Institute
Robert M Krasny, MD is a member of the following medical societies: American Roentgen Ray Society and Radiological Society of North America
Disclosure: Nothing to disclose.
Felix S Chew, MD, MBA, EdM, Professor, Department of Radiology, Vice Chairman for Radiology Informatics, Section Head of Musculoskeletal Radiology, University of Washington
Felix S Chew, MD, MBA, EdM is a member of the following medical societies: American Roentgen Ray Society, Association of University Radiologists, and Radiological Society of North America
Disclosure: Nothing to disclose.
© 1994-
by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)